Junjie Jiang

Dec 6, 2024 | mdpi.com | Junjie Jiang |Daiwen Chen |Bing Yu |Jun He

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Dec 6, 2023 | onlinelibrary.wiley.com | Hang Yang |Rui Meng |Junjie Jiang |Yan Luo

1 INTRODUCTION The treatment of non-small cell lung cancer (NSCLC) is “individualized” with targeted drugs. This approach is more effective, has fewer side effects, and is gradually replacing traditional chemotherapy (Ettinger et al., 2016; Wu et al., 2019). Epidermal growth factor receptor (EGFR) mutation is the most common agent used to target the mutation in NSCLC (Holleman et al., 2019; Loong et al., 2018).